Key Points
- Insider sale: Johannes Jacob Piete Kastelein sold 6,000 shares at an average price of $33.25 on Jan. 5 for $199,500, reducing his stake by 7.55% to 73,481 shares (worth ~$2.44M), per the SEC filing.
- Share and valuation snapshot: NAMS opened at $35.45 (up ~4.2%), has a market cap of ~$4.02B, a negative P/E of -17.29, and a 12‑month trading range of $14.06–$42.00.
- Operations and sentiment: The company missed recent quarterly expectations (EPS -$0.41 vs. -$0.38; revenue far below estimates) but analysts remain largely positive (consensus "Moderate Buy," target ~$46.73) and institutions own about 89.89% of the stock.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 2,647 shares of the company's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75. Following the completion of the transaction, the chief accounting officer owned 12,353 shares of the company's stock, valued at approximately $410,737.25. This trade represents a 17.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Louise Frederika Kooij also recently made the following trade(s):
- On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
- On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
- On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.
NewAmsterdam Pharma Stock Performance
Shares of NAMS opened at $35.45 on Thursday. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00. The stock's fifty day moving average is $36.86 and its 200-day moving average is $29.84. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of -17.29 and a beta of 0.07.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. Analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
NAMS has been the topic of several recent analyst reports. Needham & Company LLC boosted their target price on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Wednesday, November 5th. Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an "outperform" rating in a research note on Thursday, November 6th. Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. The Goldman Sachs Group lifted their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a "neutral" rating in a report on Tuesday, December 2nd. Finally, Leerink Partners reiterated an "outperform" rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $46.73.
View Our Latest Report on NAMS
Institutional Investors Weigh In On NewAmsterdam Pharma
Institutional investors and hedge funds have recently modified their holdings of the stock. Mather Group LLC. acquired a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in NewAmsterdam Pharma during the 3rd quarter worth about $30,000. Wolverine Asset Management LLC acquired a new stake in NewAmsterdam Pharma during the 3rd quarter worth about $69,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company's stock valued at $79,000 after buying an additional 662 shares in the last quarter. Finally, Avanza Fonder AB boosted its holdings in shares of NewAmsterdam Pharma by 21.0% in the second quarter. Avanza Fonder AB now owns 7,505 shares of the company's stock worth $136,000 after buying an additional 1,300 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
